Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
3.1.2 Other PEDs This group included other substances prohibited by WADA, such as non-approved substances (BPC-157) from Section S0, other anabolic agents (clenbuterol and SARMs) from Subsection S0, S1.2, peptide hormones and their releasing factors (AOD-9604, hGH 176-191, CJC-1295, ibutamoren, ipamorelin, and growth hormone-releasing peptide) from S2.2, growth factors and growth factor modulators (thymosin-4 and its derivative TB-500) from S2.3, beta-2 agonists (salbutamol and indacaterol) from S3, metabolic modulators (meldonium, GW1516, SR9009, SR9011, and insulins) from Section S4.4, and thyroid hormones
The most commonly reported events in active arms were mild and transient: injection site reactions in some subcutaneous subjects, occasional headache, and in some oral dosing arms, minor gastrointestinal tolerance issues
A patient administering 2,100mcg weekly as seven daily 300mcg injections shows better radiographic bone healing markers at six weeks than one administering 2,400mcg weekly as three 800mcg pulses
Adults across a wide age range use B12 support for different reasons
Drip Hydration
For a broader overview of the regulatory landscape, see our are research peptides legal in 2026 explainer
